Imatinib Demo

Imatinib Mesilate, the active ingredient in Imatinib Demo, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of certain hematologic and solid tumours in adult patients. GNH USA supplies Imatinib Demo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Demo targets BCR‑ABL driven malignancies and related tyrosine‑kinase pathways. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth by blocking KIT signaling. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by suppressing BCR‑ABL activity.

Adverse reactions may occur with Imatinib use.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Edema: peripheral swelling, especially of the ankles. - Muscle cramps: intermittent tightening of limb muscles. - Fatigue: reduced energy and stamina.

Serious or Rare Side Effects: - Severe neutropenia: marked drop in white blood cells, increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced heart function, presenting as shortness of breath or edema.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular complete blood count testing. - Assess liver function: check hepatic enzymes periodically. - Evaluate cardiac status: baseline ECG and cardiac assessment in at‑risk patients. - Avoid in patients with known hypersensitivity to imatinib or its excipients. - Use caution in renal impairment: adjust monitoring frequency. - Store at ambient temperature: keep in the original pack, protect from moisture.

Imatinib may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase imatinib exposure. - Potent CYP3A4 inducers (e.g., rifampin): reduce therapeutic levels. - Antacids containing aluminum or magnesium: decrease absorption if taken simultaneously. - Warfarin: may enhance anticoagulant effect and raise INR. - QT‑prolonging agents: increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam): may have altered plasma concentrations. - Digoxin: potential increase in serum levels requiring dose adjustment.